Hepatitis B Virus Vaccine for Patients with Hepatitis C Virus Infection

Chlabicz, Sławomir; Grzeszczuk, Anna

doi:10.1007/s150100070002

Cited by 12 publications

(11 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent review of studies addressing the safety and tolerability of HBV vaccine in patients with chronic hepatitis C also found few side effects [26]. Among the trials reviewed, mild local reactions occurred in 7% to 20% of those vaccinated; additionally, general reactions such as headache, fever, and nausea occurred in 2% to 19%, with no serious adverse reactions being reported.…”

Section: Vaccination Against Hepatitis B In Patients With Chronic LIVmentioning

confidence: 99%

Vaccination against hepatitis b in patients with chronic liver disease

Reiss

Keeffe

2006

Curr hepatitis rep

View full text Add to dashboard Cite

Section: Vaccination Against Hepatitis B In Patients With Chronic LIVmentioning

confidence: 99%

Vaccination against hepatitis b in patients with chronic liver disease

Reiss

Keeffe

2006

Curr hepatitis rep

View full text Add to dashboard Cite

“…In view of the role of HBV as cofactor in the development of HCV related cirrhosis and HCC, vaccination of patients with chronic hepatitis C against HBV has been advocated with the presumption of avoiding additional liver injury [62,63]. …”

Section: Epidemiology Of Hepatocellular Carcinomamentioning

confidence: 99%

Viral hepatitis and hepatocellular carcinoma

2005

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. The incidence of HCC varies considerably with the geographic area because of differences in the major causative factors. Chronic hepatitis B and C, mostly in the cirrhotic stage, are responsible for the great majority of cases of HCC worldwide. The geographic areas at the highest risk are South-East Asia and sub-Saharan Africa, here hepatitis B is highly endemic and is the main cause of HCC. In areas with an intermediate rate of HCC such as Southern Europe and Japan, hepatitis C is the predominant cause, whereas in low rate areas such as Northern Europe and the USA, HCC is often related to other factors as alcoholic liver disease. There is a rising incidence in HCC in developed countries during the last two decades, due to the increasing rate of hepatitis C infection and improvement of the clinical management of cirrhosis.

show abstract

“…Patients with chronic HCV are at increased risk of complications from acute hepatitis A virus (HAV)6, acute hepatitis B virus (HBV)7, and by chronic co-infection with HBV8 compared to those without underlying liver disease. HAV and HBV are both vaccine-preventable diseases and the vaccines have been shown to be safe and effective in patients infected with chronic HCV9.…”

Section: Introductionmentioning

confidence: 99%

Low Rates of Hepatitis A and B Vaccination in Patients with Chronic Hepatitis C at an Urban Methadone Maintenance Program

Felsen

Fishbein

Litwin

2010

Journal of Addictive Diseases

View full text Add to dashboard Cite

Aims-Patients with chronic hepatitis C virus (HCV) are at increased risk for complications of liver disease if they become infected with the hepatitis A (HAV) or hepatitis B (HBV) viruses. All major guidelines for the management of patients with chronic HCV include the recommendation for vaccination against HAV and HBV for those who are not already immune. We examined the rates of testing for HAV, HBV, and HCV, as well as rates of vaccination against HAV and HBV in patients with chronic HCV infection at a methadone maintenance program (MMP).Design, Participants, and Setting-Retrospective review of a random sample (n=207) of medical records of patients enrolled in an academically affiliated, urban MMP providing on-site primary care services. Measurements-Serostatus for HAV, HBV, and HCV and rates of vaccination for HAV and HBV in those patients with chronic HCV.Findings-Almost all patients reviewed were tested for HAV, HBV, and HCV. Of the 111 patients found to be chronically infected with HCV, 53 (48.6%) and 68 (63%) were found to lack immunity to HAV and HBV respectively. Of those lacking immunity, 29 (54.7%) and 2 (2.9%) were then vaccinated for HAV and HBV respectively.Conclusions-Despite high rates of testing for HAV, HBV, and HCV at an urban methadone maintenance program, approximately half of those with chronic HCV eligible for the HAV vaccine received it and very few of those eligible for HBV vaccine received it.

show abstract

Hepatitis B Virus Vaccine for Patients with Hepatitis C Virus Infection

Cited by 12 publications

References 58 publications

Vaccination against hepatitis b in patients with chronic liver disease

Vaccination against hepatitis b in patients with chronic liver disease

Viral hepatitis and hepatocellular carcinoma

Low Rates of Hepatitis A and B Vaccination in Patients with Chronic Hepatitis C at an Urban Methadone Maintenance Program

Contact Info

Product

Resources

About